Centivax has developed a platform technology for broad-spectrum vaccines. Our first indication is influenza, where we have achieved breakthrough results in live protection of pigs and ferrets from diverse influenza viruses. This platform and our IP are broadly applicable to many rapidly-mutating pathogens: universal vaccines for the coronavirus family and HIV are in preclinical development. Centivax is supported by the Bill and Melinda Gates Foundation, NIH, DoD, US Navy, US Army, NIIMBL, and other organizations. The team is led by CEO Jacob Glanville, who in 2012 founded and in 2020 sold a successful antibody engineering biotech (Distributed Bio) to Charles River Laboratories for $104M (with no dilutive financing). The team includes members with a combined >150 years of pharma industry experience including 50+ INDs, 4 BLAs, and over 100 discovery programs.